<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115861">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737268</url>
  </required_header>
  <id_info>
    <org_study_id>6949-CL-0022</org_study_id>
    <nct_id>NCT01737268</nct_id>
  </id_info>
  <brief_title>Long-term Study of FK949E in Elderly Bipolar Disorder Patients</brief_title>
  <official_title>Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FK949E will be administered to elderly bipolar disorder patients with major depressive
      episode for 52 weeks.  Its safety, efficacy, and plasma concentration change will be
      evaluated in an open-label manner.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>Change from Baseline to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAM-D17</measure>
    <time_frame>Change from Baseline to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HAM-D (Hamilton Depression Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Bipolar-Severity (CGI-BP-S)</measure>
    <time_frame>Change from Baseline to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, 12-lead ECGs and Labo-tests</measure>
    <time_frame>for 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>Elderly patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK949E</intervention_name>
    <description>oral</description>
    <arm_group_label>Elderly patients</arm_group_label>
    <other_name>quetiapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bipolar I or II disorder as specified in the DSM-IV-TR, with a major
             depressive episode

          -  Able to participate in the study with understanding of and compliance with subject
             requirements during the study in the investigator's or subinvestigator's opinion

          -  Male subjects must agree to take appropriate contraceptive measures with condoms
             during the study period.

          -  Female subjects must be confirmed to have no childbearing potential during the study
             period

        Exclusion Criteria:

          -  Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar
             disorder, within the last 6 months before informed consent

          -  Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect
             patient's current mental status.

          -  The Young Mania Rating Scale (YMRS) total score of 13 points or more.

          -  Nine or more mood episodes within the last 12 months before informed consent.

          -  Lack of response to at least 6-week treatment with at least 2 antidepressants for the
             current major depressive episode in the investigator's or subinvestigator's opinion

          -  The current major depressive episode persisting for more than 12 months or less than
             4 weeks before informed consent.

          -  History of substance dependence (other than caffeine and nicotine) or alcohol abuse
             or dependence.

          -  Treatment with a depot antipsychotic within the last 49 days before primary
             registration.

          -  Unable to suspend antipsychotics or antidepressants after primary registration

          -  Treatment with two or more of mood stabilizers (lithium carbonate and/or sodium
             valproate) and lamotrigine, if these drugs, except one of either drug, cannot be
             suspended after primary registration.

          -  Unable to suspend antiepileptics (except lamotrigine and sodium valproate),
             antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents,
             cerebral ameliorators, antidementia agents, or anorectics, except those specified as
             conditionally-allowed concomitant drugs, from 7 days before primary registration

          -  Electroconvulsive therapy within the last 83 days before primary registration.

          -  A possible need of psychotherapy during the study period (unless the therapy has been
             commenced at least 83 days before primary registration).

          -  The Hamilton Depression Rating Scale (HAM-D17) suicide score of 3 points or more,
             history of suicide attempt within the last 6 months before informed consent, or the
             risk of suicide in the investigator's or subinvestigator's opinion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>clintrialtrials_info@jp.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 27, 2012</lastchanged_date>
  <firstreceived_date>November 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FK949E</keyword>
  <keyword>Major depressive episode</keyword>
  <keyword>patients</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
